Posted on 09/02/2010 in Pharmaceutical Company Product News ALK-Abello announced this week that its grass allergy immunotherapy tablet GRAZAX functioned well during the final clinical study into its performance.
For the first time ever, it was confirmed that the positive effect of the tablet is sustained for two years following the completion of treatment, which lasts for a period of three years.
After the indicated course of GRAZAX treatment, hay fever symptoms were reduced in correlation with the results of previous trials.
This noticeable reduction in hay fever symptoms was accompanied by less use of symptomatic medications, the firm highlighted.
Last year, GRAZAX tablets were approved in the EU pending the outcome of this final trial, verifying the effectiveness and consistent results offered by the therapy.
In other ALK-Abello news, the organisation reported this week that it has appointed a new director of group communications.
Martin Barlebo, who takes up his role from this month onwards, holds an MA in political sciences and has previously worked for firms such as Holm Kommunikation A/S. Other news stories from 09/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
